It's not the same old lupus or Sjogren's any more: One hundred new insights, approaches, and options since 1990

Current Opinion in Rheumatology

Volumn 11, Issue 5, 1999, Pages 321-329

  Wallace, Daniel J ^a,b   Linker Israeli, Mariana ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Cedars Sinai/UCLA School of Medicine ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; AZATHIOPRINE; CLADRIBINE; CLOFAZIMINE; CLOPIDOGREL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DAPSONE; DICLOFENAC; ETRETIN; FLUOXETINE; ISOTRETINOIN; KETOPROFEN; LEFLUNOMIDE; LEPROSTATIC AGENT; MEPACRINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PENTOXIFYLLINE; PROSTAGLANDIN DERIVATIVE; RETINOID DERIVATIVE; TACROLIMUS; THALIDOMIDE; WARFARIN;

APOPTOSIS; AUTOIMMUNITY; BEHAVIOR THERAPY; CONNECTIVE TISSUE DISEASE; CYTOKINE PRODUCTION; DIAGNOSTIC TEST; DISEASE CLASSIFICATION; GENETIC SUSCEPTIBILITY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS;

HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; SJOGREN'S SYNDROME;

EID: 0032708136     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-199909000-00001     Document Type: Review

References (40)

1. Williams HJ, Alarcon GS, Joks R, Steen VD, Bulpitt K, Clegg DO, Ziminski CM, Luggen ME, St Clair EW, Wilkens RF, Yarboro C, Morgan JG, Egger MJ, Ward JR: Early undifferentiated connective tissue disease (CTD): VI. An inception cohort after 10 years: disease remissions and changes in diagnoses in well established and undifferentiated CTD. J Rheumatol 1999, 26:816-825.
2. Hochberg MC: Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997, 40:1725.
3. Wallace DJ, Pistiner M, Nessim S, Metzger AL, Klinenberg JR: Cutaneous lupus erythematosus without systemic lupus erythematosus: clinical and laboratory features. Sem Arthritis Rheum 1992, 21:221-226.
4. Wallace DJ, Quismorio FP: The elusive search for geographic clusters of systemic lupus erythematosus. Arthritis Rheum 1995, 38:1564-1567.
5. Lahita RG: Special report: adjusted lupus prevalence: results of a marketing study by the Lupus Foundation of America. Lupus 1995, 4:450-453.
6. Lawrence RC, Helmick CG, Arnett FC, Deyo RA, Felson DT, Giannini EH, Heyse SP, Hirsch R, Hochberg MC, Hunder GG, Liang MH, Pillemer SR, Steen VD, Wolfe F: Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998, 1:778-799.
7. Rahman P, Gladman DD, Urowitz MB: Smoking interferes with efficacy of antimalarial therapy in cutaneous lupus. J Rheumatol 1998, 25:1716-1719.
8. Tan FK, Arnett FC: The genetics of lupus. Curr Opin Rheumatol 1998, 10:399-408.
9. Tsokos GC: Overview of cellular immune function in systemic lupus erythematosus. In Systemic Lupus Erythematosus, 3rd ed. Edited by Lahita RG. San Diego: Academic Press 1998, 17-54.
10. Shi Y, Kaliyaperuma A, Lu L, Southwood S, Sette A, Michaels MA, Datta SK: Promiscuous presentation and recognition of nucleosomal autoepitopes in lupus: role of autoimmune T cell receptor alpha chain, J Exp Med 1998, 187:367-378.
11. Llorente L, Richaud-Patin Y, Couderc J, Alarcon-Segovia D, Ruiz-Soto R, Alcocer-Castilejos N, Alcocer-Varela J, Granados J, Bahens S, Galanaud P: Dysregulation of interleukin-10 production in relatives of patients with systemic lupus erythematosus. Arthritis Rheum 1997, 40:1429-1435.
12. Wu J, Edberg JC, Redecha PB, Bansai V, Guyre PM, Coleman K, Salmon JE, Kimberly RP: A novel polymorphism of FcgRiila (CD16) alters receptor function and predisposes to autoimmune disease. J Clin Invest 1997, 100:1059-1070.
13. Youinou P, Isenberg DA, Kalsi JK: Interplay of four idiotypes and interaction with autoantibodies in lupus patients, their relatives, and their spouses. J Autoimmunity 1996, 9:767-771.
14. CabraL AR, Alarcon-Segovia D: Autoantibodies in systemic lupus erythematosus. Curr Opin Rheumatol 1998, 10:409-416.
15. James JA, Kaufman KM, Farris AD, Taylor-Albert E, Lehman TJA, Harley JB: An increased prevalence of Epstein-Barr virus infection In young patients suggests a possible etiology for sysemic lupus erythematosus. J Clin Invest 1997, 100:3019-3026.
16. Putterman C, Kuo P, Diamond B: The structure and derivation of antibodies and autoantibodies. In Dubois' Lupus Erythematosus, 5th ed. Edited by Wallace DJ and Hahn BH. Baltimore: Williams & Wilkins 1997, 383-396.
17. Yung RL, Quddus J, Chrisp CE, Johnson KJ, Richardson BC: Mechanisms of drug induced lupus: I. Cloned Th2 cells modified with DNA methylation inhibitors in vitro cause autoimmunity in vivo. J Immunol 1995, 154:3025-3035.
18. Gladman D, Urowitz M, Gough J, MacKennon A: Fibromyalgia is a major contributor to quality of life in lupus. J Rheumatol 1997, 24:2145-2148.
19. Smolen JS, Steiner G: Mixed connective tissue disease: to be or not to be? Arthritis Rheum 1998, 41:768-777.
20. ACR Ad Hoc Committee on Neuropsychiatric Lupus Nomenclature: The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999, 42:599-608.
21. Sternberg EM, Chrousos GP, Wilder RL, Gold PW: The stress response and the regulation of inflammatory response. Annals Intern Med 1992, 117:854-866.
22. Rand JH, Wu XX, Andree HAM, Lockwood CJ, Guller S, Scher J, Harpel PC: Pregnancy loss in the antiphospholipid antibody syndrome: a possible thrombogenic mechanism. N Engl J Med 1997, 337:154-160.
23. Buyon J: Neonatal lupus, Current Opinion Rheumatol 1996, 8: 485-490.
24. Fox RI, Tomwall J, Maruyama T, Stern M: Evolving concepts of diagnosis, pathogenesis and therapy of Sjögren's syndrome, Curr Opin Rheum 1998, 10:446-456.
25. McCartney-Francis NL, Mizel DE, Frazier-Jessen M, Kulkami AB, McCarthy JB, Wahl SM: Lacrimal gland inflammation is responsible for ocular pathology in TGF-beta 1 null mice, Am J Pathol 1997, 151:1281-1288.
26. Moutsopoulos HM: Sjögren's syndrome therapy: future directions. J Rheumatol 1997 [suppl], 24:33-34.
27. Petri M: 1998 update on antiphospholipid antibodies. Curr Opin Rheumatol 1998, 10:426-430.
28. Sailer M, Burchert W, Ehrenheim C, Smid HG, Haas J, Wildhagen K, Wurster U, Deicher H: Positron emission tomography and magnetic resonance imaging for cerebral involvement in patients with systemic lupus erythematosus. J Neurol 1997, 244:186-193.
29. + Lupus Erythematosus, 5th ed. Edited by Wallace DJ and Hahn BH. Baltimore: Williams & Wilkins 1997, 19-30.
30. McLaughlin JR, Bombardier C, Farewell VT, Gladman DD, Urowitz MB: Kidney biopsy in systemic lupus erythematosus: III. Survival analysis controlling for clinical and laboratory variables. Arthritis Rheum 1994, 37:359-368.
31. Cozen L, Wallace DJ: Avascular necrosis in systemic lupus erythematosus: clinical associations and a 47-year perspective. Amer J Orthop 1998, 27:352-354.
32. Wallace DJ: Antimalarial agents and lupus. Rheum Dis Clin NA 1994, 20:243-263.
33. Arden NK, Lloyd ME, Spector TD, Hughes GRV: Safety of hormone replacement therapy in systemic lupus erythematosus. Lupus 1994, 3:11-13.
34. Kyle MV, Belcher G, Hazelman BL: Placebo-controlled study showing therapeutic benefit of lloprost in the treatment of Raynaud's phenomenon. J Rheumatol 1992; 19:1403-1406.
35. Wallace DJ: Focus on therapy: Apheresis for lupus erythematosus. Lupus 1999, 8:174-180.
36. Austin HA, Boumpas DT: Treatment of lupus nephritis. Semin Nephrol 1996, 6:527-535.
37. Strand V: Approaches to the management of systemic lupus erythematosus. Curr Opin Rheumatol 1997, 9:410-420.
38. Gladman DD: Prognosis and treatment of systemic lupus erythematosus. Curr Opin Rheumatol 1996, 8:430-437.
39. Mellemkjaer L, Andersen V, Linet MS, Gridley G, Hoover R, Olsen JH: Non-Hodgkin's lymphoma and other cancers among a cohort of patients with systemic lupus erythematosus. Arthritis Rheum 1997, 40:761-768.
40. Khamashta MA, Ruiz-Irastrorza G, Hughes GRV: SLE flares during pregnancy. Rheum Dis Clin NA, 1997, 23:15-30.